MSN Labs launches renal cancer treatment Cabolong
Hyderabad: MSN Labs, a city-based pharma company on Thursday announced the launch of Cabolong, a branded generic of Cabozantinib for treatment of renal cell carcinoma.
The company's new Oncology Division will focus on presenting a comprehensive range of affordable high quality, bio-equivalent generic cancer drugs benefitting patients in the country, MSN labs said in a press release.
"Our endeavour at MSN Labs has always been to enable swift access to affordable life-saving medicines in critical therapeutic domains. Given the rising cancer incidence in our country and overwhelming treatment costs associated with it, launch of our dedicated oncology division demonstrates our unwavering commitment to patients' health and economic well-being." MSN Group said in a statement as reported by PTI.
Cabolong is manufactured at MSN Labs' state-of-the-art facility approved by stringent global regulatory authorities like US FDA and EU GMP, it added.
MSN Laboratories had earlier entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19.
Read also: MSN Labs, DRDE ink pact for COVID drug 2-DG
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd